NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

NCT05568719

RecruitingPhase 3

Sponsor: Pfizer

Conditions: Hemophilia A, Hemophilia B

Interventions: Testing of hepatic AAV Vector integration

Countries: United States, Australia, Canada, South Korea, Sweden, Taiwan, Turkey (Türkiye)

A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.

Eligibility overview

Sex: MALE

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

-Only participants who received investigational giroctocogene fitelparvovec or fidanacogene eleparvovec and were enrolled in a Pfizer-sponsored study (C0371002, C0371003, C0371005, C3731001, C3731003) are eligible.

Exclusion Criteria:

-None

Locations (23)

Rancho Cordova, California, United States
Sacramento, California, United States
Sacramento, California, United States
Sacramento, California, United States
Sacramento, California, United States
San Francisco, California, United States
Tampa, Florida, United States
Tampa, Florida, United States
Madison, Mississippi, United States
New York, New York, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Seattle, Washington, United States
Camperdown, New South Wales, Australia
Camperdown, New South Wales, Australia
Toronto, Ontario, Canada
Seoul, South Korea
Malmö, Sweden
Taichung, Taiwan
Taipei, Taiwan
Izmir, İ̇zmir, Turkey (Türkiye)
Adana, Turkey (Türkiye)